On December 13, 2024, Justin Chakma, Chief Business Officer at ARS Pharmaceuticals Inc (SPRY, Financial), executed a sale of 144,605 shares of the company. Following this transaction, the insider now holds 136,380 shares of ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on developing novel therapies for the treatment of severe allergic reactions. The company aims to provide innovative solutions to improve patient outcomes in emergency situations.
The recent sale by Justin Chakma is part of a broader trend observed within the company. Over the past year, the insider has sold a total of 529,245 shares and has not made any purchases. This activity is consistent with the overall insider transaction history for ARS Pharmaceuticals Inc, which shows 1 insider buy and 61 insider sells over the same period.
On the day of the sale, shares of ARS Pharmaceuticals Inc were trading at $12.23 each, resulting in a market cap of $1.156 billion. Investors may want to consider this insider activity in the context of the company's valuation metrics, such as the GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow.
For more details on this transaction, please refer to the SEC Filing.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
